Mineralys Therapeutics Inc. Common Stock Q2 2025 Earnings Recap

Mineralys Therapeutics reported strong clinical trial results for lorundrostat, positioning it as a promising treatment for uncontrolled hypertension and related conditions, with significant interest from healthcare providers for future prescriptions.

Key Takeaways

• Pivotal trial data from the Launch-HTN and Advance-HTN studies demonstrated significant reductions in systolic blood pressure, published in major medical journals.
• A survey indicated that 95% of surveyed cardiologists and primary care physicians are likely to prescribe lorundrostat for patients with resistant hypertension if approved.
• The company is actively preparing for a pre-NDA meeting with the FDA in Q4 2025, signaling readiness for regulatory submission.
• Lorundrostat shows potential benefits in patients with comorbidities such as chronic kidney disease and obstructive sleep apnea, broadening its market application.
• Ongoing pre-commercial efforts include enhancing market access and payer value assessments to support lorundrostat's launch.